Coherus BioSciences, Inc. (NASDAQ:CHRS) is scheduled to announce its Q3 2017 earnings results after the market closes on Tuesday, November 7th. Analysts expect the company to announce earnings of ($0.83) per share for the quarter.
Coherus BioSciences (NASDAQ:CHRS) last announced its earnings results on Monday, August 7th. The biotechnology company reported ($1.08) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.29) by $0.21. The company had revenue of $1.40 million during the quarter. Coherus BioSciences had a negative net margin of 73.89% and a negative return on equity of 307.41%. On average, analysts expect Coherus BioSciences to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
Coherus BioSciences, Inc. (NASDAQ:CHRS) opened at $11.95 on Monday. The company has a quick ratio of 4.27, a current ratio of 4.27 and a debt-to-equity ratio of 3.27. Coherus BioSciences, Inc. has a 12 month low of $10.65 and a 12 month high of $29.59.
In other Coherus BioSciences news, insider Alan C. Herman sold 17,535 shares of the firm’s stock in a transaction that occurred on Tuesday, August 8th. The shares were sold at an average price of $15.02, for a total transaction of $263,375.70. Following the sale, the insider now owns 49,651 shares of the company’s stock, valued at $745,758.02. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 26.28% of the stock is currently owned by company insiders.
Several research analysts have recently commented on CHRS shares. Maxim Group reissued a “buy” rating and issued a $20.00 price objective (down previously from $40.00) on shares of Coherus BioSciences in a research note on Friday, September 8th. Zacks Investment Research raised shares of Coherus BioSciences from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a research note on Tuesday, August 15th. Cowen and Company reissued an “outperform” rating and issued a $45.00 price objective on shares of Coherus BioSciences in a research note on Friday, September 8th. Credit Suisse Group reissued an “outperform” rating and issued a $17.00 price objective (down previously from $24.00) on shares of Coherus BioSciences in a research note on Wednesday, September 27th. Finally, J P Morgan Chase & Co reissued an “overweight” rating and issued a $25.00 price objective (down previously from $32.00) on shares of Coherus BioSciences in a research note on Tuesday, August 8th. Three investment analysts have rated the stock with a sell rating and nine have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $32.00.
ILLEGAL ACTIVITY NOTICE: This piece of content was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://www.com-unik.info/2017/11/06/coherus-biosciences-inc-chrs-set-to-announce-quarterly-earnings-on-tuesday.html.
Coherus BioSciences Company Profile
Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.
What are top analysts saying about Coherus BioSciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Coherus BioSciences Inc. and related companies.